These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38450559)

  • 21. New Radiolabeled Exendin Analogues Show Reduced Renal Retention.
    Joosten L; Frielink C; Jansen TJP; Lobeek D; Andreae F; Konijnenberg M; Heskamp S; Gotthardt M; Brom M
    Mol Pharm; 2023 Jul; 20(7):3519-3528. PubMed ID: 37265006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours.
    Zhang H; Schuhmacher J; Waser B; Wild D; Eisenhut M; Reubi JC; Maecke HR
    Eur J Nucl Med Mol Imaging; 2007 Aug; 34(8):1198-208. PubMed ID: 17262215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Translation and First In-Human Use of [
    Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
    Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of
    Krebs S; O'Donoghue JA; Biegel E; Beattie BJ; Reidy D; Lyashchenko SK; Lewis JS; Bodei L; Weber WA; Pandit-Taskar N
    Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3047-3057. PubMed ID: 32378020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy.
    Pang Y; Zhao L; Fang J; Chen J; Meng L; Sun L; Wu H; Guo Z; Lin Q; Chen H
    J Nucl Med; 2023 Sep; 64(9):1449-1455. PubMed ID: 37321827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Internal Dosimetry of 18 F-PSMA-1007 and 68 Ga-PSMA-11-HBED-CC.
    Sharma P; Watts A; Singh H
    Clin Nucl Med; 2022 Nov; 47(11):948-953. PubMed ID: 35961365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lu-177-Labeled Hetero-Bivalent Agents Targeting PSMA and Bone Metastases for Radionuclide Therapy.
    Zha Z; Ploessl K; Choi SR; Zhao R; Jin W; Wang R; Alexoff D; Zhu L; Kung HF
    J Med Chem; 2023 Sep; 66(17):12602-12613. PubMed ID: 37670407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA.
    Ray Banerjee S; Chen Z; Pullambhatla M; Lisok A; Chen J; Mease RC; Pomper MG
    Bioconjug Chem; 2016 Jun; 27(6):1447-55. PubMed ID: 27076393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis, Quality Control, and Bench-to-Bed Translation of a New [
    Chakraborty S; Chatterjee S; Chakravarty R; Sarma HD; Nanabala R; Goswami D; Joy A; Pillai MRA
    Cancer Biother Radiopharm; 2024 Feb; 39(1):92-101. PubMed ID: 38335449
    [No Abstract]   [Full Text] [Related]  

  • 30. Improving Theranostic Gallium-68/Lutetium-177-Labeled PSMA Inhibitors with an Albumin Binder for Prostate Cancer.
    Lee BS; Kim MH; Chu SY; Jung WJ; Jeong HJ; Lee K; Kim HS; Kim MH; Kil HS; Han SJ; Lee YJ; Lee KC; Lim SM; Chi DY
    Mol Cancer Ther; 2021 Dec; 20(12):2410-2419. PubMed ID: 34725194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A radiohybrid theranostics ligand labeled with fluorine-18 and lutetium-177 for fibroblast activation protein-targeted imaging and radionuclide therapy.
    Yang T; Peng L; Qiu J; He X; Zhang D; Wu R; Liu J; Zhang X; Zha Z
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2331-2341. PubMed ID: 36864362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and validation of a kit formulation of [
    Hong H; Ploessl K; Zha Z; Wang H; Guo R; Xie Q; Zhu H; Yang Z; Zhu L; Kung HF
    Appl Radiat Isot; 2021 Mar; 169():109485. PubMed ID: 33360838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and evaluation of radiogallium-labeled long-chain fatty acid derivatives as myocardial metabolic imaging agents.
    Effendi N; Mishiro K; Wakabayashi H; Gabryel-Skrodzka M; Shiba K; Taki J; Jastrząb R; Kinuya S; Ogawa K
    PLoS One; 2021; 16(12):e0261226. PubMed ID: 34910775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
    Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW
    Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 68Ga-PSMA-HBED-CC PET/CT imaging in Black versus White South African patients with prostate carcinoma presenting with a low volume, androgen-dependent biochemical recurrence: a prospective study.
    Lengana T; van de Wiele C; Lawal I; Maes A; Ebenhan T; Boshomane T; Zeevaart JR; Ankrah A; Mokgoro N; Vorster M; Sathekge M
    Nucl Med Commun; 2018 Feb; 39(2):179-185. PubMed ID: 29257006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and evaluation of a novel 68Ga-chelate-conjugated bisphosphonate as a bone-seeking agent for PET imaging.
    Suzuki K; Satake M; Suwada J; Oshikiri S; Ashino H; Dozono H; Hino A; Kasahara H; Minamizawa T
    Nucl Med Biol; 2011 Oct; 38(7):1011-8. PubMed ID: 21982572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imaging of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-HBED-CC-PSMA PET/CT.
    Lütje S; Gomez B; Cohnen J; Umutlu L; Gotthardt M; Poeppel TD; Bockisch A; Rosenbaum-Krumme S
    Clin Nucl Med; 2017 Jan; 42(1):20-25. PubMed ID: 27846003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [
    Lau J; Kwon D; Rousseau E; Zhang Z; Zeisler J; Uribe CF; Kuo HT; Zhang C; Lin KS; Bénard F
    Mol Pharm; 2019 Nov; 16(11):4688-4695. PubMed ID: 31545614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical Characterization of DPI-4452: A
    Massière F; Wiedemann N; Borrego I; Hoehne A; Osterkamp F; Paschke M; Zboralski D; Schumann A; Bredenbeck A; Brichory F; Attinger A
    J Nucl Med; 2024 May; 65(5):761-767. PubMed ID: 38514083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.